Actively Recruiting
Investigating DPP4 Inhibitors and Tumor Cell Detection in Blood for Treating Blood Cancers
Led by University of Missouri-Columbia · Updated on 2025-12-10
50
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to better understand the role of Dipeptidyl Peptidase-4 DPP4 inhibitors in treating acute myeloid leukemia AML and other blood cancers. AML is a serious blood cancer responsible for a large number of deaths each year in the United States, and new treatments are needed. The study focuses on how DPP4 is involved in leukemia and other blood malignancies, hoping to improve personalized therapies. The study involves collecting blood and bone marrow samples from patients with various blood cancers. Researchers will analyze these samples to investigate the effect of DPP4 inhibitors on leukemia stem cells both in laboratory tests and living organisms. The study also explores whether DPP4 inhibitors can help prevent AML from coming back once it is in remission. Participants will provide blood and bone marrow samples during clinic visits or hospital stays. Researchers will monitor DPP4 inhibitor levels in blood and correlate these with patient survival over five years. The study will include laboratory tests and data collection to understand how DPP4 impacts leukemia progression. This observational study does not involve treatment but focuses on analyzing samples and survival data over time.
CONDITIONS
Brief Title
Membrane Target Detection for Leukemia Treatment
Research Team
X
Xunlei Kang, MD.PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
